October 6: The 2026 Nobel Prize in Physiology or Medicine was awarded in Stockholm on Monday to Karl Deisseroth of Stanford University and the German scientists Peter Hegemann and Georg Nagel, “for their discoveries concerning light-gated ion channels and optogenetics”. Their work lets researchers switch individual nerve cells on and off with pulses of light, and it is now being tested as a way to give some sight back to people who have gone blind.
Update, October 6 (evening): The physics prize has gone to Francis Halzen for the IceCube Neutrino Observatory. Read: Nobel Prize in Physics 2026.
Key highlights
- Winners: Karl Deisseroth (Stanford University and the Howard Hughes Medical Institute), Peter Hegemann (Humboldt University, Berlin) and Georg Nagel (University of Würzburg).
- Prize: 12 million Swedish kronor, about $1.2 million, shared between the three.
- The science: A light-sensitive protein from algae is put into nerve cells, which can then be controlled with light.
- Medicine: A gene therapy for the eye disease retinitis pigmentosa is under review by the US Food and Drug Administration.
- Left out: Several early contributors, among them Ed Boyden and Zhuo-Hua Pan. The prize can go to three people at most.
What optogenetics is
In the early 2000s Hegemann and Nagel found channelrhodopsin, a protein in the green alga Chlamydomonas that opens a channel in the cell’s membrane when light falls on it. In 2005 Deisseroth’s laboratory put the gene for that protein into nerve cells and showed that blue light could make them fire. By 2007 his team was switching nerve cells on and off in the brains of living mice.
“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” said Per Svenningsson, Chair of the Nobel Committee for Physiology or Medicine, in the official announcement. Researchers use it to work out which cells and circuits are involved in memory, sleep and behaviour, and in neurological and psychiatric disorders.
From the lab to the eye clinic
The first medical use is in the eye. Nanoscope Therapeutics has developed a single injection that delivers a light-sensitive protein to cells in the retina of people with retinitis pigmentosa. The company has said the US Food and Drug Administration accepted its application in September 2026. If approved, it would be the first optogenetic therapy on the market. Ray Therapeutics and the French company GenSight Biologics are testing similar approaches.
Who was left out
Nobel rules allow at most three winners, and more than three people helped to create optogenetics. Scientists whose early work is often cited include Ed Boyden of MIT, first author of Deisseroth’s 2005 paper; Zhuo-Hua Pan of Wayne State University; the Austrian scientist Gero Miesenböck, who made nerve cells respond to light by genetic means in 2002; and the biophysicist Ernst Bamberg, a co-author of the early channelrhodopsin papers with Nagel and Hegemann. The Nobel Assembly does not explain its choices, and its nomination records stay sealed for 50 years.
The Asia angle: the scientist who got there first
Zhuo-Hua Pan began his research career in China and moved to the United States in the 1980s for his doctorate. Pan has said that by February 2004 he had made nerve cells from the retina respond to light using channelrhodopsin, months before the experiment in Deisseroth’s laboratory that led to the 2005 paper, and that journals turned his paper down before it was accepted. It appeared in the journal Neuron in April 2006, eight months after the Stanford paper.
Pan is a vision scientist, and his experiment was done in cells of the retina, the tissue in which the first therapy is now being tested. The second author of the 2005 Stanford paper was Feng Zhang, who later became known for his work on the gene-editing tool CRISPR.
Timeline
| When | What happened |
|---|---|
| 2002–2003 | Nagel, Hegemann and colleagues describe channelrhodopsin from green algae |
| 2002 | Miesenböck makes nerve cells sensitive to light by genetic means |
| August 2005 | The Stanford paper is published in Nature Neuroscience |
| April 2006 | Pan’s paper is published in Neuron |
| 2007 | Deisseroth’s team controls nerve cells in living mice |
| September 2026 | The US regulator accepts the first application for an optogenetic therapy |
| 5 October 2026 | Nobel Prize awarded |
Compiled by The Press of Asia from the Nobel Assembly’s announcement and published research.
What comes next
The three laureates will receive the prize in Stockholm on 10 December, the anniversary of Alfred Nobel’s death. Watch also for the US regulator’s decision on the first optogenetic eye therapy, which would move the method from the laboratory into routine medicine.





